The dysregulation of Membrane-type 1 matrix metalloproteinase(MT1-MMP)has been extensively studied in numerous cancer types,and plays key roles in angiogenesis,cancer progression,and metastasis.MT1-MMP is a predictor ...The dysregulation of Membrane-type 1 matrix metalloproteinase(MT1-MMP)has been extensively studied in numerous cancer types,and plays key roles in angiogenesis,cancer progression,and metastasis.MT1-MMP is a predictor of poor prognosis in osteosarcoma(OS),yet the molecular mechanisms of disease progression are unclear.This review provides a summary of the literature relating to the gene and protein expression of MT1-MMP(MMP-14)in OS clinical samples,evaluates the expression in cell lines and experimental models,and analyses its potential role in the progression and metastasis of OS.In addition,the therapeutic potential of MT1-MMP as a drug target has been assessed.Due to the biological complexity of MMPs,inhibition has proven to be challenging.However,exploiting the expression and proteolytic capacity of MT1-MMP could open new avenues in the search for novel,safer and selective drugs for use in OS.展开更多
The membrane-type matrix metalloproteinases(MT-MMPs),an important subgroup of the wider MMP family,demonstrate widespread expression in multiple tumor types,and play key roles in cancer growth,migration,invasion and m...The membrane-type matrix metalloproteinases(MT-MMPs),an important subgroup of the wider MMP family,demonstrate widespread expression in multiple tumor types,and play key roles in cancer growth,migration,invasion and metastasis.Despite a large body of published research,relatively little information exists regarding evidence for MT-MMP expression and function in metastatic prostate cancer.This review provides an appraisal of the literature describing gene and protein expression in prostate cancer cells and clinical tissue,summarises the evidence for roles in prostate cancer progression,and examines the data relating to MT-MMP function in the development of bone metastases.Finally,the therapeutic potential of targeting MT-MMPs is considered.While MT-MMP inhibition presents a significant challenge,utilisation of MT-MMP expression and proteolytic capacity in prostate tumors is an attractive drug development opportunity.展开更多
基金This work was supported by the Bone Cancer Research Trust (No. BCRT 6218).
文摘The dysregulation of Membrane-type 1 matrix metalloproteinase(MT1-MMP)has been extensively studied in numerous cancer types,and plays key roles in angiogenesis,cancer progression,and metastasis.MT1-MMP is a predictor of poor prognosis in osteosarcoma(OS),yet the molecular mechanisms of disease progression are unclear.This review provides a summary of the literature relating to the gene and protein expression of MT1-MMP(MMP-14)in OS clinical samples,evaluates the expression in cell lines and experimental models,and analyses its potential role in the progression and metastasis of OS.In addition,the therapeutic potential of MT1-MMP as a drug target has been assessed.Due to the biological complexity of MMPs,inhibition has proven to be challenging.However,exploiting the expression and proteolytic capacity of MT1-MMP could open new avenues in the search for novel,safer and selective drugs for use in OS.
文摘The membrane-type matrix metalloproteinases(MT-MMPs),an important subgroup of the wider MMP family,demonstrate widespread expression in multiple tumor types,and play key roles in cancer growth,migration,invasion and metastasis.Despite a large body of published research,relatively little information exists regarding evidence for MT-MMP expression and function in metastatic prostate cancer.This review provides an appraisal of the literature describing gene and protein expression in prostate cancer cells and clinical tissue,summarises the evidence for roles in prostate cancer progression,and examines the data relating to MT-MMP function in the development of bone metastases.Finally,the therapeutic potential of targeting MT-MMPs is considered.While MT-MMP inhibition presents a significant challenge,utilisation of MT-MMP expression and proteolytic capacity in prostate tumors is an attractive drug development opportunity.
